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In a multivariant model inclUding these variables, as well as NYHA class,
gender, and treatment groups (flosequinan or placebo), AL was the most
significant predictor of death (P = 0.005). In patients dying with progressive
HF or of other causes, AL was a better predictor of death than NE, while in
patients dying of a sudden cardiac death, NE was a better predictor. Thus,
measurement of AL appears to be a new prognostic factor in patients with
HF. These results suggest a role for free-radical formation in the pathophys-
iologyof HF and provide a new opportunity for therapy.
In experimental models of heart failure (HF) free-radical formation has
been shown to be increased and considered to be involved in patho-
physiologic mechanisms leading to progressive ventricular dysfunction.
Adrenochromes, the products of oxidation of norepinephrine (NE) are
thought to reflect oxidative stress (amount of free-radical formation) and to
be more cytotoxic than NE. To investigate the importance of adrenochromes
in HF, we measured adrenolutins (AL), stable breakdown products of
adrenochromes, along with plasma NE, and N-terminal atrial natriuretic fac-
tor {ANFI in 257 patients at baseline entering the PROFILE study of flose-
quinan. We then related these variables to mortality (21 - progressive HF.
27 - sudden cardiac deaths and 9 - other causes) over a 20-month period.
Pre HM W2 W4 W8
PV 117 ± 22 123 ± 17 119 ± 19 111 ± 12
ANF 276 ± 199 199 ± 62 180± 110 141 ± 66
PA 53 ± 52 16 ± g 17 ± 18 14 ± 9*
PRA 46 ± 25 7 ± 3* 8 ± 7* 11 ± 18*
AVP 5.2 ± 5 O.8± 1 0.6 ± 07* 1.1 ± 1*
Congestive heart failure is associated with blood volume expansion which by
itself increases the burden on the heart. High PV with congestive heart failure
has been attributed to stimulation of the renin-aldersterone system and AVP.
The use of left ventricular assist devices as bridges to heart transplantation
has increased the survival of these patients during this critical period. We hy-
pothesized that improvement of cardiac mechanical function by HeartMate
(left ventricular assist device) is associated with a normalization of volume
load secondary to normalization of neurohumoral determinants of plasma
volume. To assess this hypothesis, we studied 15 patients (13 M: 2 F; age 50
± 9 yrs) with end stage heart failure who were cardiac transplant candidates,
before and after HeartMate 1000 (HM) implantation. We measured plasma
volume (pV, RISA). and plasma levels of atrial natiuretic hormone (ANFI. al-
dosterone (PA), renin (PRA), and arginine vasopressin (AVP). sequentially at
pre HM, and post HM (weeks 2, 4 and 8). Results:
Plasma aldosterone levels were significantly lower during high-dose than
during low-dose lisinopril treatment at both 6 hours (p < 0.03) and at 22 hours
(p < 0.04).
Conclusion: The suppression of aldosterone actiVity during chronic ACE
inhibitor therapy in patients with heart failure is dose-dependent. This pro-
vides further evidence that ACE inhibitors should be routinely prescribed in
high doses.
x± SO, P(paired t): * < 005 vs pre HM
Conclusions: The reduction of PV, PRA, PA and AVP occurs earlier than
the reduction of plasma volume and ANF after HeartMate, possibly due to
decreased pulmonary congestion and improved renal perfusion. The reduc-
tion of ANF cannot be responsible for lack of adequate decrease of plasma
volume; its reduction can be taken as a marker of improved cardiac pump
function and decreased atrial stretch.
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Mean Plasma Aldosterone Concentration(pg/ml)
Peak (6 hours) Trough (22 hours)
163.0 186.7
98.4 118.4
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PCWP BNP ANP cGMP
---C HF C HF C HF C HF
BNP-O 9 31 t 12 571 84 7451 14 16
BNP-25 8 29 273* 521* 99 910* 28* 19
BNP-50 6* 28* 611* 1053* 93 884* 31* 24*
BNP-l00 6* 26* 769* 1230* 104* 871* 32* 24*
pSD 2 4 250 284 33 149 4 6
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Their Functional Role in Heart Failure
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used as a strong, non-baroreflex mediated stimulus to vasoconstriction.
Results: Phlebotomy decreased central venous pressure (p < 0.001), but
did not change mean arterial pressure or heart rate in HF patients or con-
trols. The major findings of the study are: 1) At rest, RCBF is markedly di-
minished in HF vs normals (2.4 ± 0.1 vs 4.3 ± 0.2 mllmin/g, p < 0.001). 2)
In normal humans during phlebotomy, FBF decreased substantially (basal vs
phlebotomy: 3.3 ± 0.4 vs 2.6 ± 0.3 mllmin/100 ml, p = 0.021, and RCBF de-
creased slightly, but significantly (basal vs phlebotomy:4.3 ± 0.2 vs 4.0 ± 0.3
mllminlg, p = 0.01). 3) The small magnitude of reflex renal vasoconstriction
is not explained by the inability of the renal circulation to vasoconstrict since
the cold pressor stimulus induced substantial decreases in RCBF in normals
(basal vs cold pressor: 4.4 ± 0.1 vs 3.7 ± 0.1 mllminlg, p = 0.003). 4) In
humans with heart failure during phlebotomy, FBF did not change (basal vs
phlebotomy:2.6 ± 0.3 vs 2.7 ± 0.2 ml/min/100 ml, p = NS), but RCBF de-
creased slightly but significantly (basal vs phlebotomy:2.4 ± 0.1 vs 2.1 ± 0.1
mllmin/g, p = 0.01). Thus, in patients with heart failure, there is an abnor-
mality in cardiopulmonary baroreflex control of the forearm circulation, but
not the renal circulation.
Conclusion: This study 1) shows the power of PET to study physiologic
and pathophysiologic reflex control of the renal circulation in humans, and
2) describes the novel finding of selective dysfunction of cardiac baroreflex
control of the forearm circulation, but its preservation of the renal circulation,
in patients with heart failure.
Neil C. Davidson, Wendy J. Coutie, Allan D. Struthers. University of Dundee,
Dundee, Scotland, UK
The optimal dose of ACE inhibitor for the treatment of heart failure is highly
controversial and it is uncertain whether the neurohormonal suppression pro-
duced by these drugs is dose-dependent. We therefore compared the effects
of low-dose and high-dose lisinopril therapy on plasma levels of aldosterone,
which causes several important adverse effects including hypokalaemia, hy-
pomagnesaemia and stimulation of myocardial fibrosis. 15 patients with
LVEF < 45%, on chronic ACE inhibitor therapy, were given lisinopril 5 mg
o.d. and 20 mg o.d. for two weeks each in a randomised order. At the end
of each treatment period plasma aldosterone levels were measured, after
30 minutes bed rest, at 6 hours (peak effect) and 22 hours (trough effect)
after the dose of lisinopril. The levels of aldosterone on each dose at these
timepoints were compared using ANOVA.
Plasma atrial and brain natriuretic peptide levels (ANP and BNP) are elevated
in heart failure (HF) but their functional significance is unclear. Accordingly,
we measured plasma ANP. BNP Ipg/ml). and their second messenger cGMP
(pmol/ml) together with PCWP (mmHg) in 8 dogs, before (BNP-O) and during
infusion of synthetic BNP (25,50 and 100 nglkg/min; BNP-25, BNP-50 and
BNP-1 00). at control (C) and HF after 3 wks of pacing. Mean data and pooled
SD (pSDI from analysis of variance are shown.
*p < 0.05 vs BNP-O. 1P < 0.05 vs C
At HF, the elevated endogenous BNP and ANP (BNP-OI were unable to
increase cGMP. Exogenous BNP induced a marked rise in plasma BNP. and
also increased plasma ANP and cGMP at both C and HF. The observation that
a higher plasma BNP level than that produced endogenously in HF is needed
to elevate cGMP suggest that the increased circulating BNP may not playa
functional role, although an important paracrine role cannot be ruled out.
Furthermore, the fact that exogenous BNP increases plasma ANP despite
falling PCWP suggests that BNP may compete with ANP for the clearance
(NPR-C) receptors.
Lisinopril Dose
5 mg o.d.
20 mg o.d.
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